Exosomes occupy an awkward position: the underlying biology is legitimate and interesting, and almost everything being sold under the name in aesthetic clinics is not what the biology describes.
Extracellular vesicles are real. They carry signalling cargo between cells, they plainly matter in tissue repair, and the research base is expanding quickly. None of that is in dispute.
What is in dispute is whether a vial bought from a distributor contains a characterised, standardised, biologically active preparation of them — and whether applying it to skin, or injecting it, does anything reproducible.
Three problems, and they compound
The first is characterisation. Isolation methods vary enormously, and what comes out the other end varies with them. Two products both labelled exosomes can differ by orders of magnitude in particle count and share very little cargo. There is no meaningful equivalence between brands, which means clinical results with one tell you very little about another.
The second is regulatory. In the UK, products of this kind sit in genuinely contested territory. Many are marketed as topicals and then used in ways that breach the skin, which is a different regulatory category entirely. Practitioners who assume that a product being purchasable means it's approved for what they're doing with it are frequently wrong, and that exposure sits with them, not the distributor.
The third is evidential. The published human data is thin, mostly small, mostly unblinded, and heavily weighted toward studies with commercial involvement. That's not damning — every technology starts there — but it's a reason to describe the treatment accurately to patients rather than sell it as established.
Neither frontier nor fad
My position is that this is early. The honest framing for a patient is that we are using something biologically plausible with limited outcome data, that we cannot promise it will do anything specific, and that the price should reflect that uncertainty rather than the marketing.
What bothers me is not the science. It's the pricing. Exosome treatments are routinely sold at a premium precisely because they sound advanced, which inverts the correct relationship between evidence and cost. The least proven thing in the room should not be the most expensive.